Proteinuria Clinical Trial
Official title:
Effects of a Whole Food, Plant-Based Nutrition Program on Subjects With Chronic Kidney Disease and Proteinuria
Verified date | May 2022 |
Source | University of Rochester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test the hypothesis that lifestyle intervention consisting of a whole food, plant-based (WFPB) diet and group education will favorably impact outcomes germane to individuals with chronic kidney disease (CKD) stage 3b and 4, including blood pressure control, amount of proteinuria (protein in the urine), and preservation of glomerular filtration rate (GFR). In addition, this study will assess weight and body composition, diabetic control in subjects with diabetes as well as CKD, and quality of life. Safety of a WFPB diet in subjects with CKD will be tested with respect to the development of elevated serum potassium and phosphorus, hypoalbuminemia (low blood protein), hypotension (low blood pressure), and hypoglycemia (low blood sugar). An exploratory aim is to test the effects of a WFPB diet on the microbiome of subjects by collecting and analyzing stool samples.
Status | Terminated |
Enrollment | 3 |
Est. completion date | March 28, 2022 |
Est. primary completion date | March 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age greater than 18 years - Subjects with CKD 3b and 4 (as determined by an estimated glomerular filtration rate of = 15 ml/min but = 45 ml/min for at least three months) - Subjects with proteinuria documented at least twice with the most recent test within the last 6 months as determined by: - Urine albumin excretion rate of > 300 mg/day or urine albumin to creatinine ratio of > 300 mg/g of creatinine - Urine protein excretion rate of > 500 mg/day or urine protein to creatinine ratio of > 0.5 g/g of creatinine - If using angiotensin converting enzyme inhibitor, angiotensin receptor blockers and/or aldosterone antagonists, on a stable dose of for greater than one month - Fluent in English language - Able and willing to comply with the testing and group education schedules - Able and willing to comply with a whole-food, plant-based diet - Able and willing to give informed consent Exclusion Criteria: - Any kidney disease requiring immunosuppressive therapy - Pregnancy or intent to become pregnant in the next 12 months - Life expectancy < 12 months - History of solid organ transplant or anticipated solid organ transplant in next 12 months - History of hyperkalemia: Two potassium measurements > 5.1 Meq/L within the last three months, or history of any intervention for hyperkalemia in the last 6 months - Subjects with malabsorptive syndromes - Subjects with history of bariatric surgery or planned bariatric surgery in the next 12 months - Subjects on warfarin - Subjects with current eating disorders - Subjects with tobacco or illicit substance use - Subjects with alcohol use of > 7 drinks per week - Allergy or intolerance of a plant-based or plant-derived food (gluten, soy, etc.) - Following a vegan diet in the six months prior to consent - Major surgery within 60 days prior to consent |
Country | Name | City | State |
---|---|---|---|
United States | Highland Hospital (University of Rochester) | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
University of Rochester |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Exploratory stool microbiome evaluation | Changes in microbiome from baseline | 12 weeks (RCT) | |
Primary | Change in systolic and diastolic blood pressure from baseline | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Primary | Change in proteinuria from baseline | Urine total protein:creatinine ratio | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Primary | Change in GFR from baseline | Serum creatinine (renal function panel) and Cystatin C | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Weight changes from baseline | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | BMI changes from baseline | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Waist circumference changes from baseline | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | 8-point bioelectrical impedance analysis changes from baseline | Body composition assessment | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Hemoglobin A1c changes from baseline | Diabetic control | 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | KDQOL-36 changes from baseline | Scoring of this questionnaire consists of 5 scales (symptoms/problem list, effects of kidney disease, burden of kidney disease, SF-12 physical composite, and SF-12 mental composite). The lowest possible score for each scale is 0, indicating the worst outcome, and the best possible score is 100, indicating the best possible outcome. | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Serum potassium changes from baseline | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Serum phosphorus changes from baseline | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Serum albumin changes from baseline | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Blood glucose level changes from baseline | Fasting serum levels from all subjects; additionally, whole blood levels measured by glucometer in subjects with comorbid type 1 or type 2 diabetes mellitus | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Total cholesterol, HDL, LDL, and non-HDL cholesterol level changes from baseline | Fasting lipid panel | 1, 4, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Serum magnesium changes from baseline | 1, 4, 8, and 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Parathyroid hormone (PTH) changes from baseline | 12 weeks (RCT); 3 and 9 months on intervention diet (all subjects) | ||
Secondary | 25-hydroxycholecalciferol changes from baseline | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Fibroblast growth factor-23 changes from baseline | 12 weeks (RCT); 3 and 9 months on intervention diet (all subjects) | ||
Secondary | High sensitivity CRP changes from baseline | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | CBC with differential changes from baseline | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | ||
Secondary | Changes in nutrient intakes from baseline based on 3 day food diaries | Assess baseline compared to intervention diet and assess compliance of intervention diet over study duration | 12 weeks (RCT); 3, 6, and 9 months on intervention diet (all subjects) | |
Secondary | Changes in urinary indicators of dietary intake from baseline | 24 hour urine collection, urinary oxidation (urinary 8-isoprostane) | 12 weeks (RCT); 3 and 9 months on intervention diet (all subjects) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
Terminated |
NCT04051957 -
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
|
Phase 2 | |
Terminated |
NCT02057523 -
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02226055 -
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
|
N/A | |
Completed |
NCT02232763 -
Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria
|
Phase 3 | |
Completed |
NCT00493727 -
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
|
N/A | |
Active, not recruiting |
NCT00565396 -
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Withdrawn |
NCT02882373 -
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02327403 -
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT01773382 -
The Effects of Weight Reduction in IgA Nephropathy
|
N/A | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Withdrawn |
NCT00541619 -
Sympathetic Overactivity in Essential Hypertension
|
N/A | |
Withdrawn |
NCT00392132 -
Impact of Screening Patients With HIV for Kidney Disease
|
||
Terminated |
NCT00001978 -
Determination of Kidney Function
|
||
Recruiting |
NCT05457283 -
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
|
Phase 3 | |
Completed |
NCT04874753 -
The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT02972346 -
Availability Study of ACTH to Treat Children SRNS/SDNS
|
N/A |